EU Gene Therapy Standards: Navigating EMA’s Evolving Manufacturing and Quality Requirements

The European Union has established the most comprehensive regulatory framework in the world for the regulation of advanced therapy medicinal products, a category that encompasses gene therapy medicinal products, somatic cell therapy medicinal products, tissue-engineered products, and combined ATMPs. This framework, built upon Regulation EC 1394/2007 and implemented through a network of guidelines, annexes, and scientific recommendations from the European Medicines Agency and the Committee for Advanced Therapies, creates both a rigorous quality standard and a complex compliance landscape that manufacturers must navigate to bring gene therapies to European patients. The regulatory architecture is not static: the EMA continues to evolve its requirements through guideline revisions, concept papers, and scientific advice that reflect the rapid advancement of gene therapy science and manufacturing technology.

For organizations developing or manufacturing gene therapies for the European market, understanding the EU regulatory framework is not merely a compliance exercise but a strategic imperative that shapes every aspect of product development from early clinical trials through commercial manufacturing. The framework’s requirements for quality documentation, manufacturing standards, comparability studies, and post-authorization oversight have direct implications for IT infrastructure, manufacturing execution systems, quality management platforms, and the data architectures that support regulatory submissions and ongoing compliance. Organizations that design their digital systems with EU ATMP requirements in mind from the earliest stages of development will avoid the costly remediation and delays that result from attempting to retrofit compliance into systems designed for different regulatory paradigms.

The current period represents a particularly dynamic phase in EU gene therapy regulation, with several significant guideline revisions underway simultaneously. The EMA’s concept paper proposing revisions to Part IV of the GMP Guide for ATMPs, published in May 2025, signals substantive changes to manufacturing standards. The new guideline on investigational ATMP requirements, which came into effect in July 2025, establishes updated expectations for clinical-stage products. And the ongoing integration of ICH quality guidelines into the ATMP-specific framework is creating new requirements for quality risk management and pharmaceutical quality systems. Manufacturers must track and prepare for these evolving requirements while maintaining compliance with the current regulatory framework.

The EU ATMP Regulatory Framework

The EU regulatory framework for ATMPs is built upon multiple layers of legislation, regulation, and guidance that collectively establish the requirements for gene therapy development, manufacturing, and commercialization in Europe.

The ATMP Regulation

Regulation EC 1394/2007, the ATMP Regulation, establishes the foundational legal framework for advanced therapies in the EU. This regulation requires that all ATMPs be authorized through the centralized procedure, with marketing authorization applications evaluated by the EMA’s Committee for Advanced Therapies before referral to the Committee for Medicinal Products for Human Use for the final scientific opinion. The centralized procedure ensures that a single marketing authorization is valid across all EU member states, providing regulatory efficiency for manufacturers but also requiring that the application and supporting data meet the standards expected by the most demanding national competent authorities. The regulation also establishes specific provisions for ATMP manufacturing, including the requirement for a manufacturing authorization from the national competent authority of the member state where manufacturing takes place, the application of good manufacturing practices specific to ATMPs, and the establishment of traceability and pharmacovigilance systems appropriate to the unique characteristics of these products.

The Committee for Advanced Therapies

The CAT plays a central role in the EU ATMP regulatory system, providing the scientific expertise needed to evaluate the quality, safety, and efficacy of advanced therapies. The CAT’s responsibilities include classification of products as ATMPs, which determines the applicable regulatory pathway, scientific evaluation of marketing authorization applications, provision of scientific recommendations on quality and non-clinical aspects of ATMPs, and contribution to the development of guidelines and regulatory standards for advanced therapies. For gene therapy manufacturers, engagement with the CAT through the scientific advice and classification procedures provides an opportunity to obtain regulatory guidance early in development, reducing the risk of misalignment between the manufacturer’s development approach and the regulatory expectations that will be applied during marketing authorization evaluation.

Relationship to Other EU Regulations

Gene therapy products in the EU are subject to multiple regulatory frameworks that must be navigated simultaneously. The ATMP Regulation provides the primary product-specific framework. The Clinical Trials Regulation EU 536/2014 governs clinical investigation of ATMPs. The EU GMP Directive, implemented through the EU GMP Guide, establishes manufacturing standards. The Tissues and Cells Directives govern the procurement, testing, and distribution of human tissues and cells used as starting materials. And the EU Pharmacovigilance legislation establishes requirements for post-authorization safety monitoring. The interaction between these frameworks creates compliance complexity, particularly for autologous gene therapies where patient tissues used as starting materials fall under both the Tissues and Cells Directives and the ATMP Regulation, requiring manufacturers to comply with dual sets of requirements for material procurement, testing, and traceability.

EMA Classification and Scientific Advice

The EMA’s classification and scientific advice procedures provide manufacturers with critical early guidance that shapes development strategy and regulatory submission planning for gene therapy products.

ATMP Classification

The CAT classification procedure determines whether a product meets the definition of an ATMP and, if so, which subcategory it falls within: gene therapy medicinal product, somatic cell therapy medicinal product, tissue-engineered product, or combined ATMP. This classification has significant regulatory implications because it determines which specific guidelines and requirements apply to the product’s development and manufacturing. Gene therapy medicinal products are defined as biological medicinal products that contain an active substance which contains or consists of a recombinant nucleic acid used in or administered to human beings with a view to regulating, repairing, replacing, adding, or deleting a genetic sequence, and whose therapeutic, prophylactic, or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains or to the product of genetic expression of this sequence. Products that fall within this definition are subject to the full ATMP regulatory framework including ATMP-specific GMP requirements, centralized marketing authorization, and the CAT evaluation process.

Scientific Advice for Gene Therapies

The EMA’s scientific advice procedure allows gene therapy developers to obtain formal regulatory guidance on specific aspects of their development plan, including quality, non-clinical, and clinical development strategy. Scientific advice for ATMPs involves the CAT, which provides domain-specific expertise that supplements the general scientific advice provided by the CHMP. The EMA also offers a dedicated ATMP certification procedure that allows small and medium enterprises to obtain a scientific evaluation of quality and non-clinical data for ATMPs at an early stage of development, providing a preliminary regulatory assessment that reduces the uncertainty associated with full marketing authorization applications. Manufacturers should use these advisory mechanisms strategically, seeking guidance on the quality and manufacturing aspects that are most likely to raise questions during marketing authorization evaluation, particularly for novel manufacturing technologies, non-standard quality control strategies, and innovative approaches to demonstrating comparability after manufacturing changes.

GMP Part IV: Manufacturing Standards for ATMPs

Part IV of the EU GMP Guide establishes the specific manufacturing standards that apply to ATMPs, supplementing the general GMP requirements in Parts I and II with provisions that address the unique characteristics of advanced therapy manufacturing.

Scope and Application

GMP Part IV applies to the manufacturing of ATMPs for both commercial supply and clinical trials. Its provisions cover all aspects of manufacturing from starting material receipt through finished product release, including quality management systems, personnel qualifications and training, premises and equipment, documentation, production operations, quality control, contract manufacturing, and the specific requirements for autologous and allogeneic products. The guidelines recognize that ATMP manufacturing differs from conventional pharmaceutical manufacturing in several fundamental ways: the starting materials are often of biological origin with inherent variability, the manufacturing processes involve living cells or genetic material that cannot be terminally sterilized, the batch sizes are frequently small with some autologous products manufactured as a single unit, and the testing turnaround times may exceed the product’s shelf life, requiring release before all test results are available.

Quality Management System Requirements

Part IV requires ATMP manufacturers to establish a comprehensive pharmaceutical quality system that encompasses all aspects of manufacturing and quality control. The quality system must include written procedures for all manufacturing operations, deviation management, change control, CAPA, complaint handling, product recall, and self-inspection. For gene therapy manufacturers, the quality system must also address the specific risks associated with genetic modification including containment measures for genetically modified organisms, biosafety protocols for handling viral vectors, and environmental monitoring programs appropriate to the biological risks of the manufacturing process. The quality system documentation must be maintained in a manner that enables regulatory inspection, with clear traceability between quality system procedures, manufacturing records, and the data that supports product release decisions.

Premises and Environmental Controls

The premises requirements in Part IV establish environmental control standards that reflect the aseptic nature of ATMP manufacturing. Manufacturing of ATMPs must take place in environments that prevent contamination of the product and cross-contamination between different products or patient batches. The specific environmental classification requirements depend on the nature of the product and the manufacturing process, with open processing steps requiring Grade A conditions with Grade B background, consistent with the requirements of Annex 1 for sterile medicinal products. Part IV provides specific allowances for the use of biological safety cabinets as Grade A environments for ATMP manufacturing, recognizing that the manual manipulations characteristic of cell therapy manufacturing are often incompatible with the restricted access barrier systems and isolators that are increasingly required for conventional sterile product manufacturing. The environmental monitoring program must be designed to detect both particulate and microbiological contamination, with alert and action limits appropriate to the manufacturing environment and the product’s susceptibility to contamination.

The 2025 GMP Guideline Revision

In May 2025, the EMA published a concept paper proposing revisions to Part IV of the EU GMP Guide, initiating a revision process that will substantially update the manufacturing standards for ATMPs.

Drivers for Revision

The concept paper identifies several drivers for the GMP Part IV revision. The updated Annex 1 on sterile medicinal product manufacturing, which became effective in August 2023, introduced changes to environmental classification, contamination control strategy, and aseptic processing requirements that need to be reflected in ATMP-specific guidance. The adoption of ICH Q9 on quality risk management and ICH Q10 on pharmaceutical quality systems has established new expectations for risk-based approaches to manufacturing quality that should be integrated into ATMP GMP requirements. And the increasing maturity of the ATMP industry, with more products reaching commercial manufacturing scale, has revealed practical challenges in applying certain Part IV provisions that the revision can address based on accumulated manufacturing experience.

Key Revision Areas

The concept paper outlines several areas of focus for the revision. Cleanroom classifications and barrier systems will be clarified, with specific guidance on the expectations for isolators, RABS, and biological safety cabinets in ATMP manufacturing. The revision will maintain provisions for biosafety cabinets due to the manual manipulations associated with individualized ATMP batches, while providing clearer expectations for when more advanced barrier systems should be considered. Quality risk management integration will embed ICH Q9 principles throughout Part IV, promoting systematic risk assessment as the basis for manufacturing decisions including environmental classification, process validation scope, and the extent of in-process testing. Pharmaceutical quality system alignment will incorporate ICH Q10 expectations for management responsibility, continuous improvement, and knowledge management into the ATMP manufacturing context. And the revision will address practical issues identified through manufacturing experience, including guidance on multi-product manufacturing, campaign manufacturing of different products in shared facilities, and the management of manufacturing processes that span multiple facilities.

Clinical Trial Quality Requirements

The EMA’s guideline on quality, non-clinical, and clinical requirements for investigational ATMPs in clinical trials, which came into effect in July 2025, establishes specific expectations for gene therapy products in clinical development.

Quality Documentation for Clinical Trials

The guideline specifies the quality documentation required for clinical trial authorization applications for investigational ATMPs, including detailed information on starting materials and their qualification, description of the manufacturing process with identification of critical process parameters and in-process controls, specification of the finished product with justification for acceptance criteria, description of the analytical methods used for quality control testing, stability data supporting the proposed shelf life and storage conditions, and the quality aspects of the Investigator’s Brochure. For gene therapy products, the quality documentation must additionally address the characterization of the genetic construct including sequence identity, purity, and stability, the qualification of cell banks and viral seed stocks, the vector production process including purification and formulation, and the strategy for controlling product-related and process-related impurities.

Risk-Based Approach to Clinical Manufacturing

The guideline promotes a risk-based approach to the quality requirements for investigational ATMPs, recognizing that the level of product and process characterization evolves as clinical development progresses. Early-phase clinical trials may employ broader acceptance criteria and less extensive characterization compared to later phases, provided that patient safety is adequately assured and that the quality risk assessment supporting the clinical trial application is well-documented. This risk-based approach has important implications for IT systems, which must be capable of managing evolving specifications and acceptance criteria across clinical development phases, tracking the accumulation of manufacturing and quality data that supports the progressive tightening of specifications, and generating the quality documentation needed for clinical trial authorization applications at each phase.

Gene Therapy-Specific Quality Considerations

Gene therapy products present quality considerations that differ from both conventional pharmaceuticals and other ATMP categories, requiring specialized approaches to characterization, testing, and release.

Vector Characterization

The quality characterization of gene therapy vectors, whether viral vectors such as adeno-associated virus, lentivirus, or adenovirus, or non-viral delivery systems such as lipid nanoparticles, is a cornerstone of the EU regulatory submission. The characterization package must demonstrate the identity of the vector including the genetic sequence of the therapeutic transgene and regulatory elements, the purity of the vector preparation including quantification of process-related impurities such as host cell proteins, residual DNA, and empty capsids, the potency of the vector measured through functional assays that assess transgene expression or biological activity, and the safety of the vector including testing for replication competence, residual infectious agents, and adventitious viruses. The analytical methods used for vector characterization must be validated to the extent appropriate for the phase of development, with increasing expectations for method validation as development progresses from early clinical trials to marketing authorization.

Genetic Stability

Demonstrating the genetic stability of gene therapy products through manufacturing and storage is a critical quality requirement. The genetic construct must maintain its sequence integrity, expression capability, and therapeutic function throughout the manufacturing process, including cell banking, vector production, purification, and formulation steps. Stability studies must demonstrate that the vector maintains its identity, purity, potency, and safety characteristics throughout the proposed shelf life under the defined storage conditions. For products manufactured using cell banks, the genetic stability assessment extends to demonstrating that the master cell bank and working cell bank maintain the genetic construct with adequate fidelity across the number of passages used in commercial manufacturing.

Potency Assay Development

The development and validation of potency assays for gene therapy products is one of the most challenging quality requirements. The EMA expects potency assays that measure the mechanism of action of the gene therapy, which for most products involves demonstrating that the vector delivers the transgene to target cells and that the transgene is expressed at levels that produce the intended therapeutic effect. Developing assays that reliably measure these complex biological activities with the precision and reproducibility required for routine quality control testing and batch release is a substantial scientific and technical challenge. The IT systems supporting potency testing must manage multi-step biological assays with long turnaround times, track the complex reagent and reference standard systems that these assays require, and capture the detailed analytical data that supports the demonstration of assay validity.

Viral Vector GMP Manufacturing

Viral vector manufacturing for gene therapy products must comply with EU GMP requirements while addressing the specific challenges of producing biological materials that are both the therapeutic agent and a potential biosafety hazard.

Cell Bank and Seed Stock Systems

The cell bank system used for viral vector production must be established and maintained in accordance with ICH Q5D guidelines, with comprehensive characterization that demonstrates the identity, purity, and suitability of the cells for vector production. Master cell banks must be tested for identity, sterility, mycoplasma, and adventitious agents, with the testing panel reflecting the species of origin of the cells and the intended use in vector production. Working cell banks derived from the master cell bank must be qualified through appropriate testing, and the number of passages from the master cell bank to the production culture must be defined and controlled. For vector seed stocks, analogous principles apply, with characterization testing that demonstrates the identity of the vector, its genetic integrity, and the absence of replication-competent virus and adventitious agents.

Containment and Biosafety

Viral vector manufacturing requires containment measures that protect both the product from contamination and the environment from release of genetically modified organisms. The containment level required depends on the risk classification of the vector under the EU Deliberate Release Directive and the national biosafety regulations of the member state where manufacturing takes place. The manufacturing facility must implement physical containment through facility design and engineering controls, procedural containment through standard operating procedures and operator training, and monitoring systems that verify the effectiveness of containment measures including environmental monitoring for vector release. The IT systems supporting containment compliance must track the biosafety classification of each product manufactured in the facility, enforce containment procedures through MES-guided workflows, and manage the environmental monitoring data that demonstrates ongoing containment effectiveness.

Viral Clearance and Safety Testing

The adoption of ICH Q5A Revision 2, which addresses viral safety evaluation of biotechnology products, has implications for gene therapy manufacturing facilities that extend beyond the gene therapy products themselves. Facilities that manufacture both gene therapy vectors and other biological products must demonstrate adequate segregation and viral clearance procedures. For gene therapy products specifically, the safety testing program must include testing for replication-competent virus at appropriate stages of manufacturing, testing for adventitious agents using methods appropriate to the production system, and evaluation of the risk of recombination events that could generate novel infectious agents. The IT systems must manage the complex testing workflows, track the validation status of viral clearance steps, and maintain the documentation that demonstrates the viral safety of the manufacturing process.

Comparability and Manufacturing Changes

Manufacturing changes are inevitable throughout the lifecycle of a gene therapy product, driven by scale-up from clinical to commercial manufacturing, technology improvements, supply chain changes, and the need to add manufacturing capacity or sites. The EU regulatory framework requires manufacturers to demonstrate that changes to the manufacturing process do not adversely affect the quality, safety, or efficacy of the product through comparability studies.

Comparability Framework for Gene Therapies

The comparability assessment for gene therapy manufacturing changes must evaluate the impact of the change across multiple quality attributes including the identity, purity, potency, and safety profile of the product. The extent of the comparability assessment depends on the nature and magnitude of the change, with minor changes requiring analytical comparability assessment and significant changes requiring additional non-clinical or clinical evaluation. For gene therapy products, comparability is particularly challenging because the biological complexity of the product means that changes that appear minor at the process level may have unpredictable effects on product quality. A change in the cell culture medium used for vector production, for example, may alter the glycosylation pattern of the viral capsid, potentially affecting tissue tropism, immunogenicity, and therapeutic efficacy in ways that cannot be predicted from analytical data alone.

Digital Systems for Comparability Management

The IT infrastructure supporting comparability studies must manage the generation, analysis, and reporting of the analytical, non-clinical, and clinical data that demonstrate comparability. This includes maintaining the complete analytical methods and their validation status for comparability testing, managing the comparison datasets including pre-change and post-change manufacturing data with appropriate statistical analysis, tracking the regulatory submission and approval of comparability protocols and reports, and maintaining the change history that documents every manufacturing change throughout the product lifecycle. The data architecture must support efficient retrieval and comparison of manufacturing data across different process versions, time periods, and manufacturing sites, enabling the trend analysis and statistical evaluation that underpin robust comparability assessments.

Digital Systems for EU Compliance

The EU regulatory framework for ATMPs has specific implications for the digital systems that manufacturers deploy to support manufacturing, quality control, and regulatory compliance.

EU Annex 11 Compliance

All computerized systems used in GMP-regulated activities for ATMP manufacturing must comply with EU GMP Annex 11, which establishes requirements for system validation, data integrity, electronic records, electronic signatures, and system security. The Annex 11 requirements apply to every system in the manufacturing IT landscape including MES, LIMS, quality management systems, environmental monitoring systems, and the chain of identity platforms that manage patient-specific material tracking. Compliance requires that each system be validated through a risk-based approach, that electronic records maintain data integrity throughout their retention period, that electronic signatures are linked to the electronic record and cannot be repudiated, and that access controls prevent unauthorized use and data modification.

Data Integrity Under EU GMP

EU GMP data integrity expectations, as articulated in the PIC/S guidance on data integrity and the MHRA guidance on data governance, establish requirements that are particularly demanding for ATMP manufacturers. The ALCOA-plus principles require that all GMP-relevant data be attributable to the person who generated it, legible and permanently recorded, contemporaneous with the activity it documents, original or a certified true copy, and accurate. These requirements apply not only to the data captured in electronic systems but also to the interfaces between systems where data is transmitted, transformed, or aggregated. For ATMP manufacturers operating complex IT environments with multiple interconnected systems, ensuring data integrity across system boundaries requires careful attention to interface validation, data mapping, and the preservation of audit trail continuity as data flows between systems.

Traceability System Requirements

The EU regulatory framework requires ATMP manufacturers to maintain traceability systems that enable the tracking of products from starting material procurement through manufacturing, distribution, and administration to the patient, and from the patient back to the starting materials and manufacturing data. For gene therapy products, this traceability requirement encompasses the genetic material used in the product, the cell banks and seed stocks used in manufacturing, all materials and reagents that contact the product during manufacturing, the manufacturing process data and quality control testing data for each batch, and the distribution and administration records. The IT systems supporting traceability must maintain these linkages across the complete product lifecycle and enable rapid retrieval of traceability information in response to regulatory inquiries, quality investigations, or product recalls.

Inspection Readiness and Documentation

EU GMP inspections of ATMP manufacturing facilities are conducted by national competent authorities with the support of EMA inspectors, and may also involve inspections by authorities in other member states through the EU mutual recognition framework. Inspection readiness requires that the manufacturer’s digital systems support the efficient retrieval and presentation of the documentation that inspectors will request.

Inspection Documentation Expectations

Inspectors of ATMP facilities typically focus on several areas where digital systems play a critical role. Quality system documentation must be readily available including SOPs, deviation reports, CAPA records, change control records, and management review documentation. Manufacturing records including electronic batch records, environmental monitoring data, and equipment qualification records must be retrievable for any batch within the inspection scope. Quality control documentation including analytical method validation records, instrument qualification records, out-of-specification investigation records, and stability data must be accessible. And the traceability system must be demonstrably capable of rapid forward and backward tracing for any selected batch. The IT systems must support these retrieval requirements through efficient search and reporting capabilities that enable inspectors to drill from summary reports into supporting detail without delays that consume inspection time and create an impression of inadequate system capability.

Cross-Border Inspection Considerations

Gene therapy manufacturing that spans multiple EU member states or involves manufacturing sites outside the EU introduces additional inspection complexity. The manufacturing authorization holder in the EU is responsible for ensuring that all manufacturing operations, wherever they are performed, comply with EU GMP requirements. This responsibility extends to contract manufacturing organizations, testing laboratories, and any other facility that performs GMP-relevant activities for the product. The IT systems must support the documentation of oversight activities including supplier qualification, quality technical agreements, and the results of contract manufacturer audits, all of which may be reviewed during EU GMP inspections.

Hospital Exemption and Decentralized Manufacturing

The EU ATMP framework includes a hospital exemption provision that allows ATMPs to be prepared on a non-routine basis for individual patients in hospitals, under the professional responsibility of a medical practitioner, without requiring a marketing authorization. This provision has implications for gene therapy manufacturing that extend beyond the exempt products themselves.

Hospital Exemption Framework

The hospital exemption, established in Article 28 of the ATMP Regulation and implemented at the national level by individual member states, allows hospitals to prepare ATMPs for individual patients under conditions that differ from those required for commercially authorized products. The quality standards applied to hospital-exempt products vary by member state, creating an uneven regulatory landscape within the EU. Some member states apply GMP-equivalent standards to hospital-exempt manufacturing while others apply less stringent requirements. For gene therapy specifically, hospital exemption manufacturing typically involves academic gene therapy programs that produce vectors and modified cells in hospital-based facilities, with quality systems that may differ substantially from those of commercial manufacturers.

Implications for Digital Infrastructure

The hospital exemption pathway has implications for digital infrastructure planning at both the institutional and national levels. Hospitals engaged in exempt ATMP manufacturing must implement quality systems, documentation practices, and traceability capabilities that meet the applicable national requirements, even though these requirements may be less stringent than full GMP. The digital systems supporting hospital exemption manufacturing must still provide adequate documentation of manufacturing processes, traceability of starting materials and products, and the ability to report adverse events associated with the administered products. As the EU considers harmonization of hospital exemption standards across member states, the digital readiness of hospital-based manufacturing facilities will become increasingly important.

The Evolving Regulatory Landscape

The EU regulatory framework for gene therapies continues to evolve in response to scientific advances, manufacturing innovation, and the accumulated experience of regulating an increasingly diverse portfolio of advanced therapy products.

ICH Integration

The ongoing integration of ICH quality guidelines into the EU ATMP regulatory framework represents one of the most significant regulatory developments for gene therapy manufacturers. The incorporation of ICH Q9 quality risk management principles into GMP Part IV will require manufacturers to demonstrate systematic, documented risk assessment processes that inform manufacturing decisions. The integration of ICH Q10 pharmaceutical quality system principles will establish expectations for management responsibility, continuous improvement, and knowledge management that go beyond the documentation-centric quality systems that have traditionally characterized ATMP manufacturing. And the application of ICH Q12 principles for lifecycle management of the commercial product will influence how post-approval manufacturing changes are managed and communicated to regulatory authorities.

Regulatory Convergence with FDA

There is increasing convergence between the EU and US regulatory approaches to gene therapy manufacturing, driven by ICH harmonization, bilateral regulatory cooperation, and the practical reality that manufacturers serving both markets benefit from aligned requirements. The FDA’s January 2026 announcement on flexible CMC approaches for cell and gene therapies reflects themes that parallel the EMA’s evolving approach, including risk-based requirements that scale with product and process understanding, flexibility in specification setting based on accumulated manufacturing experience, and the recognition that gene therapy manufacturing processes are inherently more variable than conventional pharmaceutical manufacturing. Manufacturers designing IT systems for global gene therapy programs should design for the highest common standard across both regulatory frameworks, creating systems that simultaneously satisfy EU and US requirements without maintaining separate compliance documentation for each jurisdiction.

Digital Regulatory Submissions

The EU’s eCTD electronic submission format and the ongoing development of structured data submissions are creating new requirements for how gene therapy quality data is organized, formatted, and transmitted to regulatory authorities. The digital systems that generate and manage quality data must be capable of producing output in the formats required for regulatory submission, including the Module 3 quality documentation for marketing authorization applications, the clinical trial authorization documentation, and the post-approval variation submissions that accompany manufacturing changes. As regulatory authorities move toward structured data submissions that enable automated review and cross-product comparison, the IT systems that capture and manage gene therapy quality data will need to evolve to support these new submission formats.

The EU regulatory framework for gene therapies establishes standards that are among the most rigorous and comprehensive in the global pharmaceutical regulatory landscape. Navigating this framework successfully requires not only deep regulatory expertise but also digital infrastructure that supports the documentation, traceability, quality management, and data integrity requirements that permeate every aspect of the regulations. Organizations that invest in understanding the EU ATMP regulatory framework and in building digital systems designed to support EU compliance will find that this investment provides a foundation for global regulatory success, as the EU standards increasingly converge with and influence regulatory expectations in other major markets. Those that underestimate the complexity and rigor of the EU framework will encounter regulatory delays, inspection findings, and compliance costs that could have been avoided through proactive preparation and strategic investment in regulatory-ready digital infrastructure.